Biotechnology Therapeutic Vaccine Law In Russia.
1. Introduction
Biotechnology therapeutic vaccine law in Russia concerns the legal regulation of vaccines developed through biotechnology and intended to prevent, treat, or modify the progression of diseases.
Unlike conventional preventive vaccines, therapeutic vaccines are designed to stimulate or modify an individual's immune response against an existing disease. They may target cancer, chronic viral infections, certain bacterial diseases, and other conditions.
Russia regulates therapeutic vaccines through a combination of pharmaceutical legislation, biotechnology regulation, clinical-trial requirements, public-health laws, intellectual-property rules, and state pharmaceutical supervision.
The principal legal distinction is between:
Preventive vaccines – intended to prevent a disease before it develops.
Therapeutic vaccines – intended to treat an existing disease or reduce its progression.
Personalized vaccines – developed using patient-specific biological or genetic information.
Genetic and nucleic-acid vaccines – involving DNA, RNA, or other genetic technologies.
Cancer immunotherapeutic vaccines – intended to stimulate immune responses against tumour-associated antigens.
Therapeutic vaccines are not automatically subject to a separate licensing category simply because they are therapeutic. Their regulatory classification depends on their composition, mechanism of action, intended use, and applicable pharmaceutical requirements.
2. Constitutional and Legislative Framework
The Russian legal framework is based on several important laws.
| Legislation | Legal significance |
|---|---|
| Constitution of the Russian Federation, 1993 | Protects life, health, dignity, and personal autonomy |
| Federal Law No. 61-FZ of 12 April 2010 | Principal legislation governing medicinal products |
| Federal Law No. 323-FZ of 21 November 2011 | Establishes patients' rights and healthcare obligations |
| Federal Law No. 157-FZ of 17 September 1998 | Regulates immunoprophylaxis of infectious diseases |
| Federal Law No. 180-FZ of 23 June 2016 | Regulates biomedical cellular products |
| Civil Code of the Russian Federation | Governs intellectual property, contractual liability, and compensation |
| Eurasian Economic Union pharmaceutical rules | Establish common pharmaceutical registration and regulatory requirements |
Federal Law No. 61-FZ is the central legislation. It governs the development, preclinical testing, clinical trials, expert examination, registration, manufacture, quality control, distribution, and use of medicinal products. Its Article 1 expressly establishes state regulation of medicine safety, quality, and efficacy.
CIS Legislation+1
An important distinction is that a therapeutic vaccine intended to treat cancer or another existing disease may fall under pharmaceutical legislation without necessarily being a preventive vaccine covered by every provision of the Immunoprophylaxis Law.
3. Legal Classification of Therapeutic Vaccines
Therapeutic vaccines can involve different biological technologies.
A. Cancer therapeutic vaccines
These vaccines stimulate the immune system to identify and attack cancer cells.
Examples include:
Tumour-antigen vaccines.
Dendritic-cell vaccines.
Personalised neoantigen vaccines.
Peptide-based cancer vaccines.
Their legal classification depends on whether the product is regulated as a medicinal product or, where applicable, a different category of biological or cellular product.
B. Genetic and mRNA vaccines
These vaccines use genetic instructions to stimulate an immune response.
Regulatory assessment may involve:
Genetic-material safety.
Biological activity.
Stability and manufacturing consistency.
Potential immune-related adverse reactions.
Long-term safety monitoring.
C. Personalized therapeutic vaccines
These products may be developed from an individual patient's tumour or genetic profile.
Their regulation raises additional questions concerning:
Patient-specific manufacturing.
Biological sample collection.
Genetic-data protection.
Traceability and product identity.
Manufacturing quality assurance.
D. Cellular therapeutic vaccines
Some products use modified immune cells or dendritic cells to stimulate an immune response.
Where the product qualifies as a biomedical cellular product, Federal Law No. 180-FZ of 2016 may apply rather than the ordinary medicinal-product framework. The distinction is important because the law establishes a separate regulatory system for biomedical cellular products.
CIS Legislation+1
4. Development and Preclinical Testing
Before a therapeutic vaccine can enter ordinary clinical use, its developer must establish appropriate evidence of safety and quality.
Under Federal Law No. 61-FZ, preclinical research may include:
Biological testing.
Microbiological testing.
Immunological assessment.
Toxicological studies.
Pharmacological evaluation.
Assessment of biological activity.
Stability and quality testing.
For cancer vaccines, testing may also investigate whether the vaccine produces an appropriate immune response against the intended tumour antigens.
The regulator must be able to assess the scientific justification for the proposed therapeutic indication.
Legal importance: A developer cannot lawfully replace the required regulatory evidence with an unsupported claim that a vaccine is innovative, personalised, or scientifically promising.
5. Clinical Trials and Ethical Approval
Clinical trials are among the most important regulatory stages.
Article 38 of Federal Law No. 61-FZ provides for clinical trials to establish the safety, efficacy, dosage, and other relevant characteristics of medicinal products.
For therapeutic vaccines, clinical trials may examine:
Safety in patients with existing diseases.
Appropriate dosage and administration schedules.
Immune-response development.
Disease progression.
Survival or other clinically relevant outcomes.
Adverse reactions and treatment complications.
The clinical-trial process requires the appropriate regulatory permission and compliance with applicable good clinical practice requirements.
WIPO+1
Patient participation and informed consent
Article 43 of Federal Law No. 61-FZ protects patients participating in medicinal-product clinical trials.
Patients must receive information about:
The nature and purpose of the trial.
The investigational vaccine.
Expected therapeutic benefits.
Potential risks and adverse effects.
Duration and conditions of participation.
Treatment of unforeseen complications.
Insurance protection.
Confidentiality of participation.
Participation is voluntary.
Article 20 of Federal Law No. 323-FZ separately establishes the right to informed voluntary consent to medical intervention and the right to refuse medical intervention, subject to statutory exceptions.
static-0.minzdrav.gov.ru+1
This is particularly significant for experimental cancer vaccines because patients may be seriously ill and vulnerable to exaggerated promises of therapeutic success.
6. State Registration and Marketing Authorisation
A therapeutic vaccine generally requires the applicable state registration before it can be routinely marketed and used as a registered medicinal product.
The registration process involves examination of relevant documentation, including:
Pharmaceutical development information.
Manufacturing procedures.
Quality-control specifications.
Preclinical research.
Clinical-trial evidence.
Proposed therapeutic indications.
Instructions for medical use.
Safety information.
Registration must support the particular therapeutic indication claimed by the manufacturer.
For example, approval for one cancer indication should not automatically be treated as approval for every cancer type.
The Eurasian Economic Union framework is also important. Russia participates in the common pharmaceutical market governed by the EAEU Treaty and associated regulatory instruments. National and Union registration routes must therefore be considered according to the applicable transitional and registration rules.
7. Manufacturing and Good Manufacturing Practice
Therapeutic vaccines require particularly strict manufacturing controls because small variations in biological materials can affect their safety and efficacy.
Manufacturers must address:
Quality assurance
Raw-material verification.
Production-process validation.
Batch consistency.
Contamination prevention.
Sterility testing where applicable.
Biological safety
Control of biological source materials.
Testing for microbial contamination.
Monitoring of relevant biological risks.
Proper disposal of biological waste.
Cold-chain management
Many biological products require controlled storage and transportation conditions.
Failure to maintain the required temperature can affect product stability and quality.
Regulatory supervision
The Federal Service for Surveillance in Healthcare, known as Roszdravnadzor, supervises medicine circulation, including quality, clinical-trial compliance, storage, transportation, and other regulated activities.
roszdravnadzor.gov.ru+1
8. Post-Marketing Surveillance and Pharmacovigilance
Registration does not end the manufacturer's legal obligations.
Therapeutic vaccines must remain subject to appropriate safety monitoring after entering the market.
Important responsibilities include:
Collecting adverse-event reports.
Evaluating unexpected immune reactions.
Investigating manufacturing defects.
Monitoring changes in the safety profile.
Reporting relevant safety information to regulators.
Taking corrective action where necessary.
Updating product information when legally required.
If a serious safety concern arises, regulatory authorities may take measures affecting the circulation of the product.
For personalised therapeutic vaccines, traceability is especially important because regulators may need to identify the particular patient, biological material, production batch, and treatment history involved in an adverse event.
9. Patient Rights and Medical Liability
Patients receiving therapeutic vaccines are protected by general Russian healthcare legislation.
The principal rights include:
Access to accurate medical information.
Informed consent.
Refusal of medical intervention.
Medical confidentiality.
Appropriate medical care.
Compensation where legally established harm results from unlawful conduct.
Liability may arise in several situations.
| Responsible party | Possible legal responsibility |
|---|---|
| Manufacturer | Defective product, inaccurate instructions, or manufacturing failures |
| Clinical investigator | Negligence or breach of clinical-trial requirements |
| Medical institution | Improper administration or inadequate patient supervision |
| Healthcare professional | Professional misconduct or negligent treatment |
| Research sponsor | Breach of clinical-trial obligations |
| Regulatory authority | Unlawful administrative conduct, subject to applicable public-law rules |
Under Russian civil-law principles, compensation claims generally require establishing the relevant legal basis, harm, and causal connection.
Importantly, an adverse reaction does not automatically prove negligence or product defect. Some adverse reactions can occur despite proper manufacturing and administration.
cms.law+1
10. Important Russian Case Laws and Judicial Decisions
A significant legal research limitation must be recognised: publicly identifiable Russian judgments specifically addressing personalised cancer therapeutic vaccines or therapeutic mRNA vaccines are limited. Consequently, the following decisions are important analogous vaccine and healthcare cases, rather than precedents directly deciding the regulatory approval of therapeutic vaccines.
Case 1. Moscow City Court – 18 October 2018, Case No. 33-45843/2018
Relevant vaccine-liability precedent
Facts:
The claimant alleged that she suffered health complications following an influenza vaccination administered on 28 September 2016.
She sought compensation for medical expenses, rehabilitation, and moral damages.
Legal issues:
Whether vaccination caused the alleged injury.
Whether the medical institution had fulfilled its obligations.
Whether compensation could be awarded for vaccine-related harm.
Judicial significance:
The case illustrates the importance of medical evidence and establishing a causal connection between vaccination and the alleged injury.
Relevance to therapeutic vaccines:
A patient injured by an experimental cancer vaccine could similarly need to establish whether the injury resulted from a defective product, negligent administration, or another legally relevant cause.
Source:
ГАРАНТ
Case 2. Third Cassation Court of General Jurisdiction – Safronov V.N. vaccination dispute
Causation and medical negligence
Facts:
The claimant alleged that vaccination against tick-borne encephalitis resulted in subsequent health problems.
The courts examined:
Medical records.
Possible allergic reactions.
Medical contraindications.
Vaccine storage and transportation conditions.
Expert evidence concerning causation.
The court upheld the rejection of the compensation claim because the necessary causal connection between vaccination and the alleged injury had not been established.
Legal principle:
The existence of a medical problem after vaccination does not, by itself, establish that vaccination caused the problem.
Relevance:
For therapeutic biotechnology vaccines, courts may need to examine scientific evidence concerning immune reactions, manufacturing quality, and the patient's medical condition.
Source:
3kas.sudrf.ru
Case 3. Moscow Regional Court – Poliomyelitis Vaccination Complication
Informed-consent and institutional liability
Facts:
A child developed vaccine-associated paralytic poliomyelitis following administration of a second poliomyelitis vaccine.
The medical experts explained that such a complication could occur even when vaccination procedures had otherwise been followed.
However, the evidence also identified defects in the documentation of informed consent and patient management.
Judicial significance:
The appellate court awarded 50,000 roubles in moral damages.
The decision illustrates that medical institutions may face liability for procedural and informed-consent failures even where the adverse medical outcome is not necessarily attributable to negligent vaccine administration.
Relevance to therapeutic vaccines:
This is particularly important for personalised cancer vaccines and other experimental immunotherapies. Patients must receive adequate information concerning:
Experimental status.
Potential immune complications.
Available treatment alternatives.
Uncertain therapeutic benefits.
Medical monitoring requirements.
Source:
oblsud--mo.sudrf.ru
Case 4. Supreme Court of the Russian Federation – 18 April 2019, No. АКПИ19-115
Subject: Tuberculosis screening and children's access to education.
Facts:
The applicants challenged Ministry of Health methodological recommendations concerning tuberculosis screening and the assessment of children's access to educational institutions.
Judicial significance:
The Supreme Court rejected the challenge, explaining that the recommendations were not independently binding legislation and that alternative medical examination methods could be available.
Relevance:
The decision illustrates the distinction between binding regulatory requirements and non-binding medical recommendations.
For therapeutic vaccines, manufacturers and healthcare institutions must distinguish mandatory clinical-trial and registration requirements from professional guidelines and scientific recommendations.
Source:
ГАРАНТ
Case 5. Constitutional Court of the Russian Federation – 18 July 2024, No. 1802-O
Subject: Compulsory vaccination and employment restrictions.
Facts:
The applicant challenged provisions of Federal Law No. 157-FZ concerning vaccination requirements and the consequences of refusing certain vaccinations.
The dispute concerned an employee who had been suspended from work after refusing COVID-19 vaccination under applicable public-health requirements.
Judicial significance:
The Constitutional Court declined to accept the constitutional complaint for consideration. Its decision discussed the statutory framework for vaccination requirements and employment restrictions applicable to designated high-risk occupations.
Relevance:
The case helps distinguish preventive public-health vaccination from therapeutic vaccination.
A therapeutic cancer vaccine should not automatically be treated as compulsory merely because preventive vaccination can be required in particular circumstances under Russian law.
Source:
ГАРАНТ
Case 6. Constitutional Court of the Russian Federation – 24 December 2024, No. 3484-O
Subject: Constitutional rights, vaccination, and workplace restrictions.
The applicant challenged statutory provisions concerning vaccination-related employment restrictions and the disclosure of medical information.
The Constitutional Court declined to accept the complaint for consideration and discussed the interaction between:
Public-health protection.
Employment legislation.
Immunoprophylaxis requirements.
Statutory vaccination obligations.
Relevance:
This decision is relevant to the balance between individual autonomy and public-health protection.
For therapeutic vaccine programmes, patient consent and medical confidentiality remain important legal safeguards.
Source:
ГАРАНТ
11. Compensation for Therapeutic Vaccine Injuries
Russian law recognises several possible routes for compensation.
A. Manufacturer liability
A manufacturer may face civil liability where a defective medicinal product or inaccurate product information causes injury.
Relevant issues include:
Product quality.
Manufacturing defects.
Failure to comply with the registration dossier.
Incorrect product instructions.
Causation and damage.
B. Medical institution liability
A medical institution may be liable for:
Incorrect vaccine administration.
Failure to examine contraindications.
Insufficient patient information.
Improper monitoring.
Negligent medical treatment.
C. State compensation
Federal Law No. 157-FZ establishes a special social-compensation framework for specified post-vaccination complications.
The framework includes statutory compensation for qualifying post-vaccination complications, disability, and death.
However, it is important not to assume that every therapeutic vaccine automatically qualifies for these benefits. The statutory definitions and eligibility conditions must be examined, particularly where a product is administered as treatment rather than preventive immunisation.
A specialist overview of Russian pharmaceutical liability also explains the distinction between manufacturer liability, healthcare-provider liability, and special vaccine-compensation arrangements.
CMS Law+1
12. Intellectual Property Rights in Therapeutic Vaccines
Biotechnology vaccine development involves substantial intellectual-property interests.
The Russian Civil Code provides the principal framework for intellectual-property protection.
Important areas include:
1. Patent protection
Patents may protect qualifying:
Vaccine compositions.
Novel pharmaceutical formulations.
Manufacturing processes.
Biotechnology inventions.
Certain therapeutic applications.
2. Trade secrets
Manufacturers may protect confidential manufacturing processes, biological production techniques, and commercially valuable research information.
3. Research ownership
Research agreements should clarify ownership of inventions created by universities, biotechnology companies, research institutions, and individual scientists.
4. Technology transfer
Licensing agreements may regulate:
Patent rights.
Production technology.
Manufacturing know-how.
Research collaboration.
Commercial distribution.
A further issue concerns personalised neoantigen vaccines: the patentability of a technical invention must be distinguished from ownership of a patient's biological material and personal genetic information.
13. Genetic Data Protection and Biological Materials
Personalised therapeutic vaccines may require the collection and processing of highly sensitive patient information.
Relevant information may include:
DNA sequences.
Tumour-genome information.
Biomarker results.
Medical histories.
Immune-response profiles.
Biological sample information.
Federal Law No. 152-FZ of 27 July 2006 on Personal Data Protection is relevant to the processing and protection of personal data.
Federal Law No. 323-FZ also establishes medical confidentiality obligations.
Legal compliance may require:
A lawful basis for collecting and processing personal data.
Appropriate patient information and consent where required.
Protection against unauthorised access.
Appropriate controls over disclosure to research partners.
Compliance with applicable cross-border data-transfer restrictions.
These obligations are especially important when Russian researchers collaborate with foreign pharmaceutical companies or international clinical-trial sponsors.
14. Advertising and Commercialisation
Therapeutic vaccine manufacturers must comply with pharmaceutical advertising restrictions.
Advertising must not misrepresent the vaccine's:
Approved therapeutic indications.
Clinical effectiveness.
Safety profile.
Scientific evidence.
Regulatory status.
A product undergoing clinical trials cannot lawfully be marketed to patients as though it were an approved and established cancer treatment.
Particular care is necessary when commercialising personalised vaccines because individual success stories do not establish general clinical effectiveness.
15. Regulatory Authorities and Their Functions
| Authority | Principal responsibility |
|---|---|
| Ministry of Health | National healthcare and pharmaceutical policy |
| Roszdravnadzor | Medicine safety, quality, and regulatory supervision |
| Ministry of Industry and Trade | Relevant industrial and pharmaceutical manufacturing policy |
| Rospotrebnadzor | Sanitary and epidemiological supervision |
| Federal Antimonopoly Service | Applicable competition and advertising regulation |
| Rospatent | Patent and intellectual-property administration |
Roszdravnadzor has an especially important role in supervising medicinal-product circulation and monitoring compliance with pharmaceutical requirements.
roszdravnadzor.gov.ru+1
16. Major Legal Challenges
The development of therapeutic vaccines in Russia raises several unresolved or developing legal questions.
1. Personalised vaccine regulation
How should regulatory authorities evaluate vaccines manufactured individually for each patient?
2. Experimental treatment and patient protection
How can the law prevent seriously ill patients from being exposed to exaggerated claims about experimental therapies?
3. AI-assisted vaccine development
Who should be legally responsible when artificial intelligence contributes to selecting tumour antigens or designing a personalised vaccine?
4. Manufacturing liability
How should responsibility be allocated when a patient-specific vaccine contains a manufacturing defect?
5. Genetic privacy
How should patient genomic information be protected when research involves multiple institutions?
6. International collaboration
How should Russian pharmaceutical requirements interact with EAEU rules and foreign clinical-trial standards?
7. Long-term adverse effects
What evidence and monitoring obligations should apply when a vaccine produces an unexpected or delayed immune reaction?
8. Access to innovative treatment
How should the Russian healthcare system balance innovation, pharmaceutical affordability, clinical evidence, and equitable access?
17. Overall Legal Analysis
The Russian legal framework for therapeutic biotechnology vaccines is based primarily on pharmaceutical regulation, clinical-trial supervision, informed consent, product-quality requirements, and civil liability.
Federal Law No. 61-FZ establishes the principal requirements for medicinal-product development, testing, registration, manufacturing, and circulation.
Federal Law No. 323-FZ protects patient autonomy and establishes important healthcare rights.
Federal Law No. 157-FZ provides the separate framework for preventive immunoprophylaxis, while Federal Law No. 180-FZ becomes relevant when a product qualifies as a biomedical cellular product.
The judicial decisions discussed above demonstrate several important principles:
Vaccine-related injuries require appropriate medical and legal evidence.
Causation is central to compensation claims.
Informed consent is an important patient protection.
Healthcare institutions may face liability for procedural failures.
Public-health vaccination powers do not automatically extend to therapeutic treatments.
The central legal challenge is balancing biotechnology innovation with patient safety, scientific evidence, individual autonomy, and pharmaceutical accountability.
18. Conclusion
Therapeutic vaccine law in Russia represents an important intersection of biotechnology, pharmaceutical regulation, medical ethics, constitutional rights, and civil liability.
As cancer vaccines, personalised neoantigen vaccines, mRNA-based technologies, and cellular immunotherapies develop, Russian law must address increasingly complex questions concerning regulatory classification, clinical evidence, biological materials, manufacturing standards, patient consent, and compensation for injuries.
Although the existing Russian legislation provides a substantial regulatory foundation, there is no clearly established, comprehensive body of reported Russian case law specifically dealing with personalised therapeutic cancer vaccines. Existing vaccine-related judgments therefore provide useful analogous principles, but should not be represented as direct precedents on therapeutic vaccine approval.
19. Important Legal Research Sources
Federal Law No. 61-FZ – On Circulation of Medicines.
Federal Law No. 323-FZ – On Fundamentals of Health Protection.
Federal Law No. 180-FZ – On Biomedical Cellular Products.
WIPO Lex – Russian pharmaceutical legislation.
CMS – Adverse Effects of Drugs and Vaccines in Russia.
ICLRC – Legal Regulation of Vaccination.
Moscow Regional Court – Poliomyelitis vaccination dispute.
Academic note: This explanation provides a research-oriented overview, not an opinion on the legal status of a particular vaccine. For actual regulatory or litigation work, the current Russian-language consolidated legislation and applicable EAEU regulations should be checked, including amendments effective in November 2026.

comments